The transforming growth factor ␤ (TGF-␤) 1 superfamily consists of cytokines, which play important roles in regulating essential cellular functions such as proliferation, differentiation, and apoptosis (1, 2) . Their multifunctional effects are elicited through oligomeric complexes of type I and type II serine/threonine kinase receptors. TGF-␤ binding to primarily the type II receptor (T␤RII) then stabilizes the heteromeric complex with the type I receptor (T␤RI) and results in transphosphorylation and activation of T␤RI by the T␤RII. The activated T␤RI then propagates the signal through transient interaction with and phosphorylation of receptor-restricted Smads. Whereas Smad2 and Smad3 mediate TGF-␤ and activin signals, Smad1, Smad5, and Smad8 act downstream of bone morphogenetic proteins. Receptor-mediated phosphorylation occurs on two serine residues in a SSXS motif in the C-terminal domain of receptor-restricted Smads. Once phosphorylated, receptor-restricted Smads dimerize with Smad4 and translocate to the nucleus and modulate transcription of TGF-␤ target genes (1, (3) (4) (5) (6) (7) .
Smad6 and Smad7 function as inhibitors of TGF-␤ family signaling. Smad7 interacts with T␤RI, blocking the phosphorylation and activation of receptor-restricted Smads, thereby preventing further signal propagation (8 -10) . Transcription of Smad6 and Smad7 is initiated by TGF-␤ stimulation, thus providing a regulatory feedback mechanism to terminate signaling through the activated receptors (11) . In addition, Smad7 expression has been shown to be induced by other factors such as shear stress, epidermal growth factor, phorbol ester, interferon-␥, and TNF-␣, suggesting that its transcription may serve as a regulatory mechanism integrating and modulating the physiological response of different signaling pathways (11) (12) (13) (14) (15) .
Elimination or clonal deletion of self-reactive B cells during development is mediated through apoptosis and is essential for maintenance of immune tolerance. Failure to eliminate immature B cells results in lymphoproliferation and the development of autoimmune diseases and cancer (16) . The mouse immature B cell line, WEHI 231, has been used as an in vitro model system to study B cell tolerance and apoptosis (17) (18) (19) . Apoptosis in these cells can be induced after membrane interaction with antibodies against cell surface IgM chains (anti-IgM) as well as by TGF-␤ (20Ϫ22). A signal for abrogating or rescuing WEHI 231 cells from anti-IgM-mediated growth arrest and apoptosis can be generated by concomitant signaling through CD40 (22) . CD40 is a transmembrane glycoprotein that is predominantly expressed by B cells (23) . It is structurally related to the TNF receptor family and plays a critical role in promoting cell survival, immunoglobulin class switching, and memory cell formation (24) .
CD40 has no intrinsic enzymatic activity but interacts with adapter molecules of the TNF receptor-associated factor (TRAF) family, which couple to multiple signaling pathways, including members of the mitogen-activated protein kinase pathway, Janus tyrosine kinase/Stat3, S6 kinase, phosphatidylinositol 3-kinase/Akt kinase, and NFB (25) (26) (27) (28) (29) . It remains unclear how all these signaling pathways contribute to the B cell response to CD40. Recent studies, however, have focused on the roles of phosphatidylinositol 3-kinase/Akt kinase and NFB in CD40-mediated survival in B-lymphocytes. Using a RAG2-deficient complementation model, it has been shown that B-lymphocytes isolated from phosphatidylinositol 3-kinase-deficient mice have a diminished proliferative response to CD-40 ligand (30) . Also, the phosphatidylinositol 3-kinase inhibitor, LY294002, induces growth arrest and apoptosis in a B cell lymphoma cell line, and their CD40-mediated rescue was shown to be phosphatidylinositol 3-kinase-dependent (31) . NFB plays a vital role in B-lymphocyte survival. Agents that decrease NFB/Rel activity promote apoptosis, whereas inducers of cell survival such as interleukin-6, platelet-derived growth factor, and CD40L up-regulate NFB/Rel activity (32) . Furthermore, recent evidence demonstrates that NFB can serve as a target for Akt kinase, resulting in its activation and consequent anti-apoptotic activity (33, 34) . These studies demonstrate that, although CD40 may elicit the activation of numerous signaling pathways, the proliferative and anti-apoptotic response of B cells to CD40 ligand may be mediated through the phosphatidylinositol 3-kinase/Akt/NFB pathway.
In this study we demonstrate that CD40 activation protects WEHI 231 cells from TGF-␤-induced apoptosis and is associated with induction of Smad7 expression. The induction of Smad7 by CD40 is NFB-dependent. We also demonstrate that Smad7 overexpression abolishes the growth inhibitory and apoptotic effect of TGF-␤ in a dose-dependent manner. The proliferative and anti-apoptotic effects of Smad7 are specific for TGF-␤ and do not affect IgM-induced growth arrest or apoptosis.
EXPERIMENTAL PROCEDURES
Materials-TGF-␤2 was a generous gift from Genzyme Inc. (Cambridge, MA) and was used at a concentration of 10 ng/ml. Purified anti-mouse and anti-human CD40 (␣-CD40) was obtained from Pharmingen (San Diego, CA), and anti-mouse and anti-human IgM (␣-IgM), N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), pyrrolidine dithiocarbamate (PDTC), and reagent chemicals were obtained from Sigma. Protease inhibitor mixture tablets were purchased from Roche Molecular Biochemicals. Primary antibodies were employed at a 1:1000 dilution and were obtained from the following vendors: goat anti-Smad7 from Santa Cruz Biotechnology (Santa Cruz, CA), rabbit anti-Smad2 and rabbit anti-Smad3 from Zymed Laboratories Inc. (San Francisco, CA), rabbit anti-phospho-Smad2 from Upstate Biotechnology Corp. (Lake Placid, NY), and mouse anti-FLAG M2 from Sigma; the Smad7 antibody was a gift from Drs. Susumu Itoh and P. ten Dijke, The Netherlands. Secondary antibodies were used at a 1:2000 dilution and were obtained from the following vendors: anti-mouse-IgG-HRP from Accurate Antibodies (San Diego, CA), anti-goat-IgG-HRP from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-rabbit-IgG-horseradish peroxidase from Bio-Rad. Oligonucleotide primers were obtained from Operon Technologies, Inc. (Alameda, CA).
Cell Culture and Transfection-WEHI 231 cells were maintained at a density of 2 ϫ 10 4 cells/ml in Dulbecco's modified Eagle's medium/ F-12 medium supplemented with 5% fetal calf serum, 30 M 2-mercaptoethanol, and antibiotics (100 units/ml penicillin and 100 g/ml streptomycin). Retroviral supernatants were prepared by transfecting Phoenix A packaging cells using the calcium phosphate method with either the empty vector pBabePuro, FLAG-tagged-Smad7, FLAGtagged-Smad2 dominant negative (DN) or FLAG-tagged-Smad3 DN in pBabePuro. The medium was collected 24 h post-transfection and used as a source of virus. For infection of WEHI 231 cells, 1 ϫ 10 5 cells were resuspended in 1 ml of retroviral supernatant containing 1 g/ml polybrene and incubated for 24 h. Infected cells were washed and allowed to recover for 48 h in complete growth media before selection in media containing 0.5 mg/ml puromycin. Single clones were isolated using a limiting dilution technique, and the level of Smad7 expression, Smad2 DN expression, or Smad3 DN expression was determined by immunoblotting cell lysates with anti-Smad7, anti-Smad2, anti-Smad3, or anti-FLAG M2 antibodies.
Growth Inhibition Assay-WEHI 231 cells (5 ϫ 10 4 cells/ml) were cultured at 37°C in the absence or presence of TGF-␤ (10 ng/ml), anti-mouse CD40 (100 ng/ml), anti-mouse IgM (3 g/ml), or a combination of each of these for either 24 or 48 h, as indicated. During the last 4 h of each treatment, cells were pulsed with 2 Ci/ml [ 3 H]methylthymidine (ICN Biomedicals, Irvine, CA). Cells and media were collected and applied to GF-C glass fiber filters pre-wetted with 10% trichloroacetic acid in a vacuum filtration unit. The individual filters were washed 2 ϫ 10 ml with ice-cold 10% trichloroacetic acid, and the filters were counted in scintillation fluid (35) .
Apoptosis Assays-Two methods were used to measure apoptosis. Apoptosis was detected by TUNEL using the APO-BRDU TM kit (Pharmingen). Briefly, at the end of each treatment, cells were washed and resuspended for 15 min in ice-cold 1% paraformaldehyde (freshly prepared in phosphate-buffered saline). The cells were further fixed in 70% ethanol overnight, and TUNEL was performed according to the manufacturer's instructions. Apoptosis was also measured using the cell death detection ELISA plus kit (Roche Molecular Biochemicals) following the kit protocol. Briefly, at the end of each treatment, cells were lysed and centrifuged, and the supernatant, containing the cytoplasmic fraction, was applied to streptavidin-coated microplates. A mix of biotinylated anti-DNA antibody and peroxidase-conjugated anti-histone antibody was added to the wells, and binding was allowed for 2 h. The plates were washed thoroughly followed by the addition of 2,2Ј-azino-di[3-ethylbenzthiazolin-sulfonate] (ABTS) substrate. Color development was monitored spectrophotometrically at 405 nm.
Western Blot Analysis-Western blot analysis was performed as described previously (36) . Briefly, 25-50 g of whole cell lysates were separated by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P membrane (Millipore, Bedford, MA). The membrane was incubated for 1 h in blocking buffer (phosphate-buffered saline containing 0.05% Tween 20 and 5% nonfat dry milk) followed by a 2-h incubation with primary antibody in blocking buffer. After extensive washing, the blot was incubated with secondary antibody for 1 h and processed using the Renaissance chemiluminescence reagent (PerkinElmer Life Sciences) according to the manufacturer's directions. For detection of Smad7, 3% bovine serum albumin was used for the primary antibody dilution instead of nonfat dry milk.
RNA Preparation and Analysis-RNA was prepared using the RNeasy kit from Qiagen (Valencia, CA) according to the instructions provided. Briefly, 1 ϫ 10 7 cells were homogenized, mixed with 70% ethanol, and applied to RNA purification columns. After extensive washing, RNA was eluted in H 2 O, and its concentration was determined spectrophotometrically. RT-PCR was performed using the Titan TM one tube RT-PCR kit (Roche Molecular Biochemicals). Briefly, 1 g of RNA was reverse-transcribed and PCR-amplified in the same tube following the manufacturer's instructions. During the amplification, the cDNA template was denatured at 94°C, annealed at 60°C, and extended at 60°C for 1 min each and amplified for 33 cycles. The sequences of the specific Smad7 primers, which amplified a 250-base pair fragment, were 5Ј-GAAGTCAAGAGGCTGTGTTGC-3Ј for the forward primer and 5Ј-CAGGCTCCAGAAGAAGTTGG-3Ј for the reverse primer. Glyceraldehyde-3-phosphate dehydrogenase was amplified as a positive control to yield a 1-kilobase pair product after 18 cycles using mouse-specific glyceraldehyde-3-phosphate dehydrogenase amplimers (CLONTECH, San Francisco, CA). The PCR products obtained were visualized on a 1% agarose gel. 5 g of a 100-base pair DNA ladder (Roche Molecular Biochemicals) was used as a marker. Determination of Smad7 mRNA levels by Northern analysis was performed using 15 g of total RNA as described previously using a 32 P-labeled Smad7 cDNA probe (37) .
Cellular Fractionation and EMSA-Nuclear and cytosolic extract preparation and EMSA experiments were performed as described previously (38) . Briefly, 1 ϫ 10 7 cells were resuspended in a hypotonic buffer (10 mM HEPES, pH 8, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol plus protease inhibitors), and the nuclear pellet obtained upon centrifugation was extracted in a high salt buffer (20 mM HEPES, pH 8, 25% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol plus protease inhibitors). The protein concentration of the extracts was determined using Bradford's reagent (Pierce). EMSA binding reactions were performed using 10 g of nuclear extract and 32 P-labeled NFB oligonucleotide. Samples were analyzed for complex formation on a 6% non-denaturing gel. Nuclear localization of Smad2 was determined by separating 20 g of nuclear and 100 g of cytoplasmic extracts by SDSpolyacrylamide gel electrophoresis on a 10% gel followed by Western blot analysis with anti-Smad2 antibody, as described above.
RESULTS

CD40 Stimulation Antagonizes TGF-␤-induced Growth
Inhibition and Apoptosis-It has previously been demonstrated that both anti-IgM (i.e. cross-linking of the B cell antigen receptor) and TGF-␤ can induce growth inhibition and apoptosis in WEHI 231 B-lymphocytes (21, 22) . Although it is well established that costimulation of cells with anti-CD40 can rescue cells from anti-IgM-induced apoptosis, the anti-apoptotic effects of the CD40 survival pathway on TGF-␤-induced cell death are less characterized (22, 39 -41) . To examine the effects of CD40 on TGF-␤-induced apoptosis, WEHI 231 cells were treated with anti-CD40, TGF-␤, or combinations thereof, and both growth inhibition and apoptosis were monitored. Cells were also treated with anti-IgM as a positive control for growth inhibition and apoptosis. As shown in Fig. 1 , stimulation of CD40 with anti-CD40 had little effect on cell growth, as measured by [ 3 H]thymidine incorporation (Fig. 1A) , or apoptosis, as measured by ELISA (Fig. 1B) . As expected, treatment of the cells with TGF-␤ or anti-IgM induced both growth arrest (Fig. 1A) and apoptosis (Fig. 1B) . TGF-␤ and anti-IgM each induced an approximately 60 -65% inhibition of cell growth. TGF-␤ treatment resulted in a 4 -5-fold induction in apoptosis, whereas anti-IgM was a more potent inducer of apoptosis, resulting in an approximately 7-10-fold induction. However, costimulation of the cells with anti-CD40 reversed the growth inhibitory effects and apoptosis induced by anti-IgM or TGF-␤ treatment (Fig. 1B) . Thus, stimulation of CD40 in the presence of TGF-␤ resulted in only a 12% decrease in [ 3 H]thymidine incorporation (Fig. 1A) and reversed the apoptotic effects of TGF-␤ to near basal levels (Fig. 1B) . Also, costimulation of CD40 abrogates both anti-IgM-induced growth inhibition (Fig.   1A ) and apoptosis (Fig. 1B) . To demonstrate that the anti-CD40 rescue of TGF-␤-induced apoptosis was not unique to WEHI 231 cells, we performed similar experiments in Ramos cells, a human B-lymphocyte cell line (42, 43) . As shown in Fig. 1C , costimulation of the CD40 receptor inhibited the apoptotic effects of both TGF-␤ and anti-IgM in Ramos cells.
Anti-CD40 Induces Smad7 Expression through Activation of NF-B-Smad7 has been identified as a negative regulator of TGF-␤ signaling through its ability to interact with ligandactivated type I receptors, thus interfering with the phosphorylation of regulatory Smad2 and/or Smad3 by the receptor (8 -10, 12) . We reasoned that Smad7 expression may be induced by anti-CD40 to suppress TGF-␤-induced apoptosis. As shown in Fig. 2 , treatment of WEHI 231 cells with anti-CD40 increased the steady state mRNA levels of Smad7, as measured by RT-PCR ( Fig. 2A) or Northern analysis (Fig. 2B ). This increase was maximal within 30 min, persisted for up to 2 h, and then declined to near basal levels at 4 h. Smad7 protein was induced by anti-CD40 in a time-dependent manner, with an increase in expression observed within 1 h and peaking at 8 h (Fig. 2C) . Peak levels of Smad7 induced by anti-CD40 (8-h time point) represented approximately 2-3-fold less Smad7 than a WEHI-231 clone, which constitutively overexpressed Smad7, clone 7.2 (see below). These results demonstrate that anti-CD40 induces Smad7 expression and suggest that Smad7 plays a role not only in blocking TGF-␤-mediated growth arrest, as has been previously demonstrated (8) , but also in TGF-␤-induced apoptosis. Furthermore, they suggest that induced expression of the inhibitory Smad7 by anti-CD40 may be the mechanism by which the survival pathway in these cells suppresses the TGF-␤ apoptotic response. Recently, TNF␣-induced Smad7 expression was shown to be mediated through the NFB transcription factor (14) . Furthermore, CD40 receptor activation in WEHI 231 cells increases IB degradation, maintains NFB/Rel activity, and results in apoptotic rescue (41, 44, 45) . We reasoned, therefore, that the induction of Smad7 by anti-CD40 may depend on NFB. To answer this question we investigated the effect of two inhibitors of the NFB signaling pathway, TPCK and PDTC, on anti-CD40 induction of Smad7 (Fig. 3) . These two inhibitors block NFB activation by different mechanisms, by preventing either degradation of IB (TPCK) or phosphorylation-dependent dissociation of NF-B from IB (PDTC) (44, 46) . As a control, we first determined whether anti-CD40 treatment increased NFB binding activity, as determined by EMSA (Fig.  3A) . The results show the presence of considerable amounts of two complexes, a p50⅐p50 complex and a p50⅐p65 complex, in untreated WEHI 231 cells. The amount of active NFB complex increased upon 30 min and 1 h of anti-CD40 treatment, and the addition of TGF-␤ did not seem to have any effect on the complex formation. The two complexes were completely eliminated in the presence of TPCK, and TPCK also abolished the activation of NFB by anti-CD40. These results are consistent with those previously reported for NFB activity in WEHI 231 cells, i.e. that basal NFB binding activity is high and increased by anti-CD40 and that TPCK totally abolishes NFB binding activity (45) .
We next performed RT-PCR (Fig. 3B) and Northern ( for the indicated times. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified as an internal control. The PCR products were separated on a 1% agarose gel. B, Northern analysis of 15 g of the same samples as those used in panel A. Equal loading was demonstrated by ethidium bromide staining the total RNA. C, Western blot analysis of Smad7 protein induction was performed with 30 g of whole cell extracts prepared from WEHI 231 cells treated with 100 ng/ml anti-CD40 antibody for the indicated times. Smad7-overexpressing WEHI-231 clone 7.2 and Smad7-transfected COS cells (COS-S7) were used as positive controls.
FIG. 3. Anti-CD40 induces Smad7 expression through the transcription factor NFB.
A, nuclear extracts were prepared from WEHI 231 cells after the indicated treatments, and EMSA was performed as described. The p50⅐p65 and p50⅐p50 complexes bound to radiolabeled oligonucleotide specific for NFkB were visualized after autoradiography. Treatment of WEHI 231 cells was for 30 min or 1 h (␣-CD40 30 min or ␣-CD40 1 h) with 100 ng/ml anti-CD40 or for 1 h with 100 M TPCK alone. For combination treatments, cells were treated for a total of 1 h receiving either 100 M TPCK or 10 ng/ml TGF-␤ for 30 min before the addition of 100 ng/ml ␣-CD40 for an additional 30 min (␣-CD40 ϩ TPCK; ␣-CD40 ϩ TGF-␤). Untreated cells were used as control (Cont.). B, TPCK and PDTC block the induction of Smad7 by ␣-CD40. RT-PCR analysis of cells that were untreated (Cont.) or treated for 30 min with 100 ng/ml anti-CD40 (␣-CD40) and 1 h with either 100 M TPCK or 25 M PDTC. When combined, anti-CD40 was added during the final 30 min of the 1-h incubation with TPCK (␣-CD40 ϩ TPCK) or PDTC (␣-CD40 ϩ PDTC). RNA was isolated, and RT-PCR was performed as described under "Experimental Procedures." RT-PCR was also performed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from the same samples as an internal control. The PCR products were separated on a 1% agarose gel. C, Northern analysis of Smad7 mRNA levels induced by ␣-CD40 in the absence or presence of TPCK. The same samples (15 g of total RNA) as those analyzed in panel B were run on agarose-formaldehyde gels, blotted and hybridized with a 32 P-labeled Smad7 cDNA probe.
Smad7 expression by itself was sufficient to inhibit TGF-␤-induced apoptosis in WEHI 231 cells. We retrovirally infected cells to overexpress FLAG-tagged Smad7, and single cell-derived stable clones were selected in puromycin. Three stable Smad7-overexpressing WEHI 231 clones, designated 7.1, 7.2, and 7.4, were chosen for study. As shown in Fig. 4A , Western blot analyses using either anti-FLAG M2 antisera or antiSmad7 antisera showed that the vector control clone expressed undetectable levels of basal Smad7 protein. The three independent Smad7 clones demonstrated different levels of Smad7 overexpression. Clone 7.1 expressed the lowest levels of exogenous Smad7, clone 7.4 displayed intermediate expression levels, and clone 7.2 showed the highest expression levels (Fig.  4A) .
These stable Smad7 clones were further characterized for their responsiveness to TGF-␤ treatment. Since Smad7 has been shown to block receptor-induced phosphorylation of Smad2, one of the earliest events in TGF-␤ signaling, the status of TGF-␤-mediated Smad2 phosphorylation, was determined in the Smad7-overexpressing clones (Fig. 4B) . Smad7 clones were incubated in the absence or presence of TGF-␤ for 1 h and analyzed by Western blotting using a phospho-Smad2-specific antibody. Vector control cells showed the highest levels of TGF-␤-induced Smad2 phosphorylation, whereas Smad2 phosphorylation was decreased in the Smad7-overexpressing clones (upper panel, Fig. 4B ). This decrease correlated in a dose-dependent manner with the respective level of Smad7 expression. Clone 7.2, the clone expressing the highest amount of Smad7, demonstrated the lowest level of TGF-␤-induced Smad2 phosphorylation. The lower panel of Fig. 4B shows Western blot analysis of Smad2 protein in the same samples as those used in the upper panel to demonstrate equal loading of protein. Since decreased Smad2 phosphorylation should lead to impaired translocation of Smad2 into the nucleus, we examined the level of TGF-␤-induced Smad2 nuclear localization in cellular fractionation studies (Fig. 4C) . In the vector control cells, TGF-␤ treatment led to an increase in nuclear localization of Smad2 and a concomitant decrease in Smad2 cytoplasmic levels. In the Smad7-overexpressing clone 7.2, the accumulation of nuclear Smad2 in response to TGF-␤ was decreased, and cytoplasmic Smad2 levels were more evenly maintained.
Increased Smad7 Expression Inhibits TGF-␤-induced
Apoptosis-Having demonstrated that increased Smad7 levels could modulate two initial events in the TGF-␤-signaling pathway, we investigated the effect of Smad7 overexpression on TGF-␤-induced growth inhibition and apoptosis (Fig. 5) . Although vector control cells exhibited a 52% growth inhibition in response to TGF-␤, the growth inhibitory effect of TGF-␤ was
FIG. 5. Overexpression of Smad7 blocks TGF-␤-mediated growth inhibition and apoptosis. A, growth inhibition of cells was monitored by [
3 H]thymidine incorporation. Vector control and Smad7-overexpressing WEHI 231 clones 7.1, 7.2, and 7.4 were either left untreated or were treated with TGF-␤ (10 ng/ml) for 24 h. Incorporation of thymidine was measured as described under "Experimental Procedures." B and C, apoptosis was detected by TUNEL (B) and ELISA (C), with cells treated in an identical manner as described above. The results represent the means of three independent experiments performed in triplicate.
FIG. 4. Overexpression of Smad7 in WEHI 231 clones and effect on Smad2 phosphorylation and nuclear localization.
A, Western blot analyses of cell lysates prepared from Smad7-overexpressing WEHI 231 clones designated 7.1, 7.2, and 7.4 using anti-FLAG M2 antibody or anti-Smad7 antibody. Unstimulated WEHI 231 vector control cells and Smad7-transfected COS cells (COS-S7) were used as negative and positive controls, respectively. B, Western blot analysis of Smad2 phosphorylation in TGF-␤-treated Smad7-overexpressing clones. Cell lysates were prepared from untreated (Ϫ) or 1 h TGF␤Ϫtreated (ϩ, 10 ng/ml) Smad7 clones 7.1, 7.2, 7.4 and vector control cells and subjected to Western blot analysis using a specific anti-phospho Smad2 antibody as described under "Experimental Procedures" (upper panel). The same samples as those in the upper panel were subjected to Western blot analysis using anti-Smad2 (lower panel). C, Western blot analysis of TGF-␤-induced Smad2 translocation from the cytosol to the nucleus. Vector control cells or Smad 7-overexpressing clone 7.2 (the clone overexpessing the highest level of Smad7) were left untreated (Ϫ) or treated for 1 h with 10 ng/ml TGF-␤ (ϩ) and subjected to cellular fractionation, as described under "Experimental Procedures." Nuclear and cytosolic extracts were analyzed by Western blotting using anti-Smad2 antibody.
reduced to 15% in the Smad7-overexpressing clone 7.2 (Fig.  5A) . The intermediate Smad7-overexpressing clone 7.4 showed about 30% growth inhibition, and the lowest Smad7-overexpressing clone 7.1 showed a response similar to that of control cells. Similarly, when TGF-␤-induced apoptosis in these clones was monitored by TUNEL (Fig. 5B) and ELISA (Fig. 5C ) assays, there was an inverse correlation between level of Smad7 overexpression and susceptibility to TGF-␤-mediated apoptosis. TGF-␤-induced apoptosis was lowest in the highest Smad7 overexpressing clone 7.2. Furthermore, high overexpression of Smad7 not only blocked TGF-␤-induced apoptosis but also lowered the basal levels of apoptosis observed in WEHI 231 cells (Fig. 5, B and C) .
Overexpression of Dominant Negative Versions of Smad2 or Smad3 Inhibits TGF-␤-induced Growth Inhibition and Apoptosis-
We retrovirally infected WEHI 231 cells with DN forms of Smad2 and Smad3 and were able to isolate clones overexpressing DN-Smad2 (clones 2.1 and 2.6) and DN-Smad3 (clones 3.1, 3.3, and 3.8). Western blot analysis of the Smad2 DN clones using anti-Smad2 antibody showed that vector control cells expressed detectable amounts of endogeneous Smad2 protein (Fig. 6A) . The Smad2 DN-overexpressing clones also showed a slower migrating band, representing the FLAG-tagged Smad2 DN, in addition to the endogeneous Smad2 band. Clone 2.1 showed a higher level of exogeneous Smad2 DN expression as compared with the clone 2.6, whereas the endogenous levels of Smad2 were unaltered. Western blot analysis of the Smad3 DN clones using anti-Smad3 antisera showed that the vector control expressed undetectable levels of endogenous Smad3 protein. The three Smad3 DN clones expressed different levels exogeneous Smad3 (Fig. 6B) . Clone 3.3 showed the highest level of Smad3 DN expression, whereas clones 3.8 and 3.1 showed intermediate levels.
These stable Smad2 DN and Smad3 DN clones were further characterized for their responsiveness to TGF-␤ treatment. We investigated the effect of Smad2 DN and Smad3 DN overexpression on TGF-␤-induced growth inhibition and apoptosis ( Fig. 6C and 6D) . Although vector control cells exhibited a 58% growth inhibition in response to TGF-␤, no growth inhibitory effect of TGF-␤ was observed in any of the Smad2 DN or Smad3 DN-overexpressing clones (Fig. 6C) . Similarly, when TGF-␤-induced apoptosis in these clones was monitored by TUNEL assay (Fig. 6D) , there was no effect of TGF-␤ on Smad2 DN and Smad3 DN-overexpressing clones, whereas the vector control cells showed about a 4 -5-fold induction of apoptosis. Thus, the expression of dominant negative Smad2 and Smad3 completely abrogates TGF-␤-mediated growth inhibition and apoptosis.
Smad7 Specifically Inhibits TGF-␤-induced Apoptosis-Finally, we wished to establish whether the effect of Smad7 was restricted to the growth inhibitory and apoptotic effects of TGF-␤ or extended to the anti-IgM-mediated growth arrest and apoptosis. For these experiments, clone 7.2, which expressed the highest level of Smad7, was left untreated or treated with TGF-␤ or anti-IgM for 48 h and assayed for growth inhibition and apoptosis using TUNEL as well as ELISA assays (Fig. 7) . As shown in Fig. 7A , TGF-␤ produced no growth inhibition in the 7.2 clone, whereas anti-IgM was able to inhibit the growth of these cells by approximately 90%. When the apoptotic responses of the 7.2 clone to TGF-␤ or anti-IgM were examined, identical results were observed; Smad7 overexpression blocked TGF-␤-induced apoptosis but did not affect anti-IgM-induced apoptosis (Fig. 7, B and C) . These results demonstrate that Smad7 is not a universal regulator of growth arrest and apoptosis in WEHI 231 cells but selectively modulates the TGF-␤-signaling pathway. DISCUSSION TGF-␤ is an important regulator of cell growth and is essential for maintenance of normal immunological homeostasis and lymphocyte proliferation (1, 2, 16) . Lymphocytes as well as a few other cell types respond to TGF-␤ by undergoing apoptosis; however, the mechanisms regulating this process are not well understood and appear to be cell-specific. The ability of TGF-␤ to induce apoptosis in immature B cells may be a major mechanism controlling lymphocyte growth and subsequently regulating the immune response (20 -22) . In this study, we demonstrate that apoptosis induced by TGF-␤ in pre-B-lymphocytes can be rescued by stimulation with an anti-CD40 antibody. The anti-apoptotic effect of anti-CD40 is associated with an NFBdependent induction of Smad7, a TGF-␤-signaling pathway inhibitor. Overexpression of exogenous Smad7 specifically abrogates TGF-␤-induced apoptosis without affecting anti-IgMinduced cell death.
The growth inhibitory and apoptotic effects of TGF-␤ and anti-IgM in B-lymphocytes have previously been characterized and share many of the same signaling events. Thus, TGF-␤ and anti-IgM both block cells in late G 1 with an accompanying decrease in the level of c-myc, and both modulate the activity of Rb, p53, p21Waf1/Cip1, p27, cyclin A, caspase protease family members, and NFB and thereby induce cells to growth arrest and apoptosis (40, 46 -49) . Consistent with these similarities in signaling, it was proposed that the effects of anti-IgM were mediated through autocrine production of TGF-␤, especially since anti-IgM induces the production of active TGF-␤ in WEHI 231 cells. On the other hand, neutralizing antibodies to TGF-␤ have no effect on anti-IgM-induced pRb phosphorylation and growth arrest (21) . Our findings now reveal another commonality between growth arrest and apoptosis induced by anti-IgM or TGF-␤. Indeed, stimulation of the cells with anti-CD40 inhibits both signaling pathways induced by either TGF-␤ or anti-IgM and, thus, rescues cells from apoptosis induced by either stimulus. Mechanistically, however, the induction of Smad7 by anti-CD40 is specific in blocking TGF-␤-induced growth arrest and apoptosis and has no effect on the anti-IgMinduced effects. In addition, anti-IgM does not induce phosphorylation of Smad2. 2 We therefore conclude that CD40 induces at least two different inhibitory pathways. One of them results in induction of Smad7 expression and specifically blocks the TGF-␤-induced response, whereas another inhibitory pathway or protein, distinct from Smad7, inhibits anti-IgM-induced cell death. Thus, our results support the idea that, at the membrane level, TGF-␤ and anti-IgM induce growth arrest and apoptosis through two independent pathways. This does not exclude the possibility that the downstream pathways of TGF-␤ and IgM-signaling merge into a common pathway mediating apoptosis, In this regard, CD40 activates anti-apoptotic genes such as Bcl-x L , which inhibit both anti-IgM-and TGF-␤-induced apoptosis (39, 51, 52) . The existence of a common pathway mediating both anti-IgM-and TGF-␤-induced apoptosis awaits further studies.
Smad7 is an inhibitor of signaling by the TGF-␤-activated Smads (8, 10, 53) . Its expression is induced by TGF-␤ itself, and Smad7 is therefore postulated to mediate an auto-inhibitory feedback loop to down-regulate TGF-␤ signaling. Recent results (13) (14) (15) have shown that other cytokines and growth factors can induce Smad7 expression. For example, interferon-␥ induces Smad7 expression through a Janus tyrosine kinase 1/Stat1-dependent mechanism, and this induction of Smad7 has been proposed to mediate the antagonistic effects of interferon-␥ on TGF-␤ signaling (13) . Also lipopolysaccharide and TNF-␣ can induce Smad7 expression, thereby inhibiting TGF-␤-signaling, and this induction occurs through an NFB/RelAdependent mechanism (14) . Our results are consistent with these findings in that they demonstrate another context in which antagonistic pathways cross-talk with TGF-␤ signaling through Smad7. In our study, the CD40-induced survival pathway antagonizes the TGF-␤-induced apoptotic pathway through an NFB-dependent induction of Smad7. Our study is the first demonstration that the CD40-induced survival pathway antagonizes the growth inhibitory and apoptotic responses to TGF-␤ through Smad7.
The critical role of NFB in the induction of Smad7 is supported by not only our results with CD40 induction but also by previous results using RelA-defective fibroblasts, demonstrating that TNF␣ induction of Smad7 requires NFB (14) . It has 2 S. Patil, G. M. Wildey, and P. H. Howe, unpublished data. also been reported that the 5Ј-flanking region of the Smad7 gene contains multiple potential NFB sites (54, 55) . The role of NFB in antagonizing apoptosis in WEHI 231 cells is well documented as is its induction by CD40. The signaling intermediates linking the CD40 receptor and NFB are currently under investigation. It is tempting to speculate that, as reported with other anti-apoptotic ligands, the phosphatidylinositol 3-kinase/Akt kinase pathway couples the CD40 receptor to NFB activation.
Several previous reports implicate Smads in apoptosis. Smad2 and Smad3 have both been proposed to play an active role in activin-and TGF-␤-mediated cell death in epithelial cells, and their activity is enhanced by Smad4 (56, 57) . Our results that dominant negative forms of Smad2 and Smad3 block TGF-␤-induced apoptosis are consistent with these findings. Smad7 has also been reported to be induced in response to activin and to suppress activin-mediated apoptosis in a B cell hybridoma (58, 59) . In contrast, Smad7 induces apoptosis in prostatic carcinoma cells, suggesting some cell type-dependent differences (50) . Our data now show that the induction of Smad7 expression by anti-CD40 may be a key event that leads to suppression of TGF-␤-induced apoptosis. Together with previous findings, our data support the hypothesis that the TGF-␤ receptor-activated Smads activate or repress transcription of key genes involved in cell death or survival.
In summary, we demonstrate that CD40 receptor activation rescues WEHI 231 cells from TGF-␤-induced growth arrest and apoptosis. The antagonism is associated with an up-regulation of Smad7 expression. We demonstrate that the induction of Smad7 by anti-CD40 is NFB-dependent. In addition, we show that overexpressed Smad7 blocks TGF-␤-mediated growth inhibition and apoptosis without affecting anti-IgM-induced apoptosis. Self-tolerance and autoimmunity requires that only a small population of immature B cells survive in an environment that is selectively tuned toward cell death. Our results provide insight into the mechanism used by cells to subvert the apoptotic effects of TGF-␤ and thereby survive.
